Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An addition or correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilsbacher, J. L.
Right arrow Articles by Cobb, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilsbacher, J. L.
Right arrow Articles by Cobb, M. H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 24, 16988-16994, June 11, 1999


Phosphorylation of MAP Kinases by MAP/ERK Involves Multiple Regions of MAP Kinases*

Julie L. WilsbacherDagger §, Elizabeth J. Goldsmith, and Melanie H. CobbDagger parallel

From the Departments of Dagger  Pharmacology and  Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas 75235-9041

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mitogen-activated protein (MAP) kinases are activated with great specificity by MAP/ERK kinases (MEKs). The basis for the specific activation is not understood. In this study chimeras composed of two MAP kinases, extracellular signal-regulated protein kinase 2 and p38, were assayed in vitro for phosphorylation and activation by different MEK isoforms to probe the requirements for productive interaction of MAP kinases with MEKs. Experimental results and modeling support the conclusion that the specificity of MEK/MAP kinase phosphorylation results from multiple contacts, including surfaces in both the N- and C-terminal domains.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mitogen-activated protein (MAP)1 kinase or extracellular signal-regulated protein kinase (ERK) cascades are present in all eukaryotes and are utilized in almost all signal transduction pathways originating from receptors at the cell surface (1, 2). A plethora of different stimuli, including growth factors, cytokines, heat shock, and ultraviolet light, can initiate signaling through these cascades. Each cascade consists of a three kinase module: a MAP kinase, a MAP kinase/ERK kinase (MEK) that activates the MAP kinase, and a MEK kinase (MEKK) that activates the MEK (3). The MAP kinase in each cascade preferentially phosphorylates substrates with a serine or threonine followed by a proline. There are three mammalian MAP kinase modules that have been extensively studied. These include the ERK1/2 module, the c-Jun N-terminal protein kinase/stress-activated protein kinase module, and the p38 module. ERK3, ERK4, and ERK5 and other p38 isoforms have also been identified, but the cascades leading to activation of these kinases are not well characterized (4-11).

Like other protein kinases, the MAP kinases are folded into two domains (12). The smaller N-terminal domain is composed mostly of beta  strands, whereas the C-terminal domain is made up of alpha  helices. ATP binds between the two domains, and protein substrate is believed to bind on the surface of the C-terminal domain. Alignment of the amino acid sequences of many protein kinases reveals a common core catalytic domain of 250-300 residues encoding the two-domain structure (13). Protein kinases possess 12 conserved stretches of amino acids within their catalytic domains known as subdomains (13-15). These conserved elements as well as unique structures contribute to catalysis by and regulation of protein kinases. The functions of several of the conserved and unique structural motifs are known. A glycine-rich loop in the N-terminal domain, termed the phosphate anchor ribbon, has a role in binding ATP. Also in the N-terminal domain, subdomain III encodes the C helix, which contains an invariant Glu involved in binding MgATP (16, 17). This helix is important for maintaining an open domain conformation in unphosphorylated ERK2 (18), aligning catalytic residues in Src (19) and Cdk2 (20), and binding to the cyclin regulatory subunit in Cdk2 (21). The activation loop, known as the phosphorylation lip in MAP kinases, is a poorly conserved element in the C-terminal domain and contains the two MAP kinase phosphorylation site residues within a TXY sequence. Also in the C-terminal domain is the MAP kinase insert. It is composed of 32 residues and is only found in the MAP kinases and the Cdks. The MAP kinase insert and a loop consisting of residues 199-205 of ERK2 interact with the phosphorylation lip in the unphosphorylated form of ERK2. Finally, a loop at the C terminus of the MAP kinases, L16 or the C-terminal tail, wraps around the back of the structure and interacts with the N-terminal domain (18).

The crystal structures of unphosphorylated and phosphorylated ERK2 and unphosphorylated p38 have been solved (18, 22-24). Several important differences exist between the structures of the unphosphorylated forms of ERK2 and p38. There is a wider domain separation in p38 than in ERK2. The phosphorylation lip in p38 is six residues shorter and has a different conformation. In p38 the lip is folded up between the two domains, and the C-terminal portion of the lip forms a turn of helix that blocks the P+1 specificity pocket. This pocket directs the proline specificity of MAP kinases. The axis of the C helix is rotated, and the N terminus of this helix is shifted by 6 Å relative to the helix in ERK2. The helix at the end of L16 is extended by 7 Å, and there is an increase in the hydrophilicity of residues that form contacts between L16 and the N-terminal domain. This results in a less intimate interaction between L16 and the N-terminal domain in p38 (22, 24).

Within MAP kinase cascades, the MEKs are the most specific enzymes. These dual specificity kinases activate their respective MAP kinase substrates by phosphorylating the threonine and tyrosine of the specific TXY sequence located in the phosphorylation lip. The only known substrates of MEK1 and MEK2 are ERK1 and ERK2 (25). Other MEKs also phosphorylate only a small subset of the MAP kinase family. For example, MEK3 and MEK6 will only phosphorylate p38 isoforms, whereas MEK5 will only phosphorylate ERK5 (26-28). In addition, the MEKs require native MAP kinases as substrates; they will not phosphorylate denatured proteins or peptides derived from the phosphorylation lip (25). Little is known about the structural basis of the specificity of interactions between MEKs and MAP kinases despite information from the crystal structures of ERK2 and p38.

Previous in vitro studies concluded that neither the phosphorylation lip length nor the residue between the phosphorylation sites is a critical element for directing MEK specificity (29, 30). Brunet and Pouysségur (31) measured the in vivo activities of chimeras of p38 and ERK1 after treatment of transfected cells with stimuli that activated either p38 or ERK1. Based on these findings they proposed that a 40-residue stretch of amino acids within subdomains III and IV of p38 was important for directing the specificity of activation. In addition, they suggested that the C helix within subdomain III was the key element for recognition of MAP kinases by MEKs.

To define structural elements of the MAP kinases that are required to direct specific recognition by MEKs, chimeras of ERK2 and p38 were tested for phosphorylation and activation by five different MEKs in vitro. Compilation of the data reveals multiple spatially segregated contacts in the MEK/MAP kinase interface.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Generation of Mutants and Purification of Proteins-- Restriction sites were inserted at the ends of subdomains II and IV and at residue 326 of ERK2 and residue 322 of p38 with the QuikChange kit (Stratagene, La Jolla, CA). ERK2IIright-arrowCT contains all the restriction sites as well as sites at the ends of subdomains III and V, and p38II contains the site at subdomain II. The resulting plasmids were used to create ERK2-p38 chimeras. His6-tagged proteins were expressed and purified as described previously (32) or by batch binding to Ni2+-nitrilotriacetic acid-agarose (Qiagen). Protein concentrations were determined with the BCA assay (Pierce) and by comparison of Coomassie Blue-stained bands after SDS-polyacrylamide gel electrophoresis. Phosphorylated His6-MEK1, GST-MEK2, and His6-MEK3 were purified from a previously described coexpression system (33), and GST-MEK4 and GST-MEK6 were purified and activated by GST-MEKK-C (34) essentially as described (29).

Phosphorylation and Activity Assays-- Phosphorylation and activity assays were performed essentially as described (29). Activity of ERK2, p38, or chimeras was determined using myelin basic protein (Sigma) as substrate. One-dimensional phosphoamino acid analysis was performed as described (35).

Time Courses of Phosphorylation and Activity-- Assays were performed as described (29), but reactions were stopped at the times indicated in Figs. 5 and 6 for MEK2 and MEK6, respectively. For MEKs 1, 3, and 4, 50-µl aliquots were removed from one large reaction mix and stopped by addition to 15 µl of 5× SDS sample buffer.

Western Blotting-- 20 ng of ERK2 or each chimera from the time course reactions with MEK2 and MEK6 were resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Blots were probed with an antibody specific for phosphorylated ERK2, V803 (Promega), and an antibody that recognizes phosphorylated and unphosphorylated ERK2, Y691.

Phosphatase Treatment-- ERK2 or chimeras were incubated with an equimolar amount of PTP1 at 30 °C for 30 min. Sodium orthovanadate was added to one set of reactions at time 0 and to an identical set at 30 min. Kinase assays with MEK2 were then performed as above, but they were stopped after 1 min.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MEKs recognize the native MAP kinase structure with considerable selectivity. The primary sequence surrounding the TXY phosphorylation sites of the ERKs is not sufficient to determine MEK recognition. Neither peptides derived from the double phosphorylation site nor denatured proteins are phosphorylated by MEKs (25). These findings support the conclusion that MEKs require specific conformations or secondary determinants for productive interaction with their MAP kinase substrates. We wished to identify the structural features of MAP kinases that allow MEKs to distinguish among them as substrates. To do this we created chimeras between ERK2 and p38 that contained selected intact structural elements from each enzyme (Fig. 1A). The chimeras were composed of ERK2 and p38 because a related set of chimeras had been tested in transfected cells (31), and the structures of both of these MAP kinases were available for analysis (18, 22, 24). The chimeras were expressed and purified and then tested in vitro for activation by MEK family members, MEKs 1, 2, 3, 4, and 6, which phosphorylate ERK2 or p38 in vitro. Measurements included rate and extent of phosphorylation, phosphoamino acids, recognition by antibodies selective for phosphorylated ERK2, and activated activity relative to the wild type proteins. ERK2 and p38 proteins containing inserted restriction sites were also purified and tested as controls.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 1.   Schematic and structural representation of ERK2, p38, and chimeras. A, conserved subdomains I-XI including VIa and VIb are indicated by blocks in ERK2 and p38. Odd numbers are shown. Subdomains from ERK2 are white, and subdomains from p38 are gray. The chimeras were named according to the subdomains that were exchanged. B, structural representation of MAP kinase domains using ERK2 as the model. The C-terminal domain is shown in blue. The N-terminal domain includes residues in white (subdomains I and II), red (subdomains III and IV, which include the C helix and beta  strands 4 and 5), and yellow (L16). Chimeras swapped the white, red, and yellow structures as indicated in A and the text.

The MAP kinase catalytic core contains two domains. The N-terminal domain is composed of N-terminal sequence (white and red in Fig. 1B) and the C-terminal tail, L16 (yellow in Fig. 1B), and is primarily involved in binding ATP. In the MAP kinases L16 lies on the surface of the N-terminal domain. The C-terminal domain (blue in Fig. 1B) binds the protein substrate. To identify important structural features, we first created a chimera, PIVECTP, which contained one of its two major structural domains from each kinase (Fig. 1). This chimera contained the larger C-terminal structural domain from ERK2 and the smaller N-terminal domain from p38. The p38 elements making up the N-terminal domain are the N terminus through subdomain IV and L16 (shown in white, red, and yellow in Fig. 1B).

We examined phosphorylation of this chimera by MEKs, the amino acids phosphorylated, and its activity after phosphorylation. This chimera was phosphorylated by MEK1 and MEK2 and by MEK3, MEK4, and MEK6, although the stoichiometry of phosphorylation by MEK3/4/6 was lower (Fig. 2). The rates of phosphorylation of the chimera by MEK2 and MEK1 were similar to the rates of phosphorylation of wild type ERK2 by these MEKs (see Figs. 5A and 7A). Likewise, the rates of phosphorylation of this chimera by MEK6 and MEK3 were similar to their rates of phosphorylation of p38 (see Figs. 6A and 7B). In each case, both tyrosine and threonine were phosphorylated (see Fig. 5C and 6C). These results indicated that interaction determinants were present in both domains. All five MEKs activated PIVECTP, and in each case the activity was proportional to the extent of phosphorylation, with MEK4 being the least effective (Figs. 2 and 3). The activity of this unphosphorylated chimera was similar to that of wild type ERK2. Maximal activity was about 15% of the activity of wild type ERK2 (Fig. 3). This may be due to imperfect folding of the chimera.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 2.   Phosphorylation of chimeras by MEK isoforms. Relative stoichiometry of phosphate incorporation into ERK2, PIVECTP, PIVE, PIIE, EIIPIVE, EIIP, and p38 by the indicated MEKs. Data for each MEK are expressed relative to stoichiometry of phosphorylation of ERK2 by MEK1 and MEK2 and of p38 by MEK3, MEK4, and MEK6. Data are the means ± S.E. of three to five independent experiments.


View larger version (16K):
[in this window]
[in a new window]
  		Fig. 3.   Kinase activity of chimeras after phosphorylation by MEK isoforms. Relative myelin basic protein kinase activity of ERK2, PIVECTP, PIVE, PIIE, EIIPIVE, and EIIP after phosphorylation by the indicated MEKs. Data are expressed relative to specific activity of ERK2 after phosphorylation by MEK2, set to 1. Data are the means ± S.E. of three to five independent experiments.

Inclusion of residues from p38 in the N-terminal domain of the chimera allowed phosphorylation by MEK3/6 in addition to MEK1/2. We next wanted to determine which structural motifs within the N-terminal domain were responsible for this expanded interaction. Therefore, three additional chimeras containing less of the N-terminal domain of p38 were constructed and analyzed as described next.

To determine the contribution of L16 (yellow in Fig. 1B) to phosphorylation by MEK, the PIVE chimera, which had all of the N-terminal domain except L16 from p38, was generated. It contained p38 residues from the N terminus through subdomain IV and ERK2 residues from subdomain V through the C terminus (Fig. 1A). Its activity in the unphosphorylated state was similar to wild type ERK2. This chimera was phosphorylated by MEK1, MEK2, and MEK6 but not by MEK3 or MEK4 (Fig. 2). All three MEKs that phosphorylated PIVE activated it equally (Fig. 3). It had stimulated protein kinase activity about 20% of that of ERK2. The rates of phosphorylation of PIVE by MEK1, MEK2, and MEK6 were similar to the rates of phosphorylation of the wild type proteins (see Figs. 5A, 6A, and 7A). These results suggested that the C-terminal tail within the N-terminal domain contributed to activation by MEK3.

EIIPIVE had only p38 subdomains III and IV, which contained the C helix and beta  strands 4 and 5 (red in Fig. 1B). Without phosphorylation by MEK, this chimera had slightly higher activity than wild type ERK2. EIIPIVE was phosphorylated and activated by MEK1 and MEK2 (Figs. 2 and 3). When phosphorylated, this chimera demonstrated decreased activity relative to wild type ERK2 (Fig. 3). MEK3, MEK4, and MEK6 did not phosphorylate it. Therefore, the C helix, beta 4, and beta 5 of MAP kinases were not sufficient for phosphorylation of a MAP kinase by these MEKs. EIIPIVE also was phosphorylated by MEK1 and MEK2 at rates similar to the rates of phosphorylation of ERK2 (see Figs. 5A and 7A).

To determine the role of the first two subdomains (white in Fig. 1B) in phosphorylation by MEKs, PIIE was tested. This chimera contained p38 residues in the N terminus through subdomain II and ERK2 residues in subdomain III through the C terminus (Fig. 1A). This chimera had activity comparable with that of unphosphorylated ERK2. Once again, only MEK1 and MEK2 phosphorylated and activated this chimera (Figs. 2 and 3). The rates of phosphorylation of PIIE by MEK1 and MEK2 were similar to the rates of phosphorylation of wild type ERK2 by MEK1 and MEK2 (see Fig. 5A and 7A). Results from these four chimeras indicated that many p38 residues must be present in the N-terminal domain of each chimera for phosphorylation by the p38-specific MEKs.

We wanted to determine whether any differences existed in the pattern of phosphorylation and activation by MEKs if the other MAP kinase was at the N terminus of the chimera. Thus, we expressed a reciprocal chimera, EIIP. EIIP contained ERK2 residues from the N terminus through subdomain II (white in Fig. 1B) and p38 residues from subdomain III through the C terminus. This chimera was phosphorylated by MEK4 and MEK6 but not by MEK1, MEK2, or MEK3 (Fig. 2). The time courses of phosphorylation were slightly more rapid (see Fig. 7C). This chimera had very low basal activity, less than 1% of wild type ERK2, suggesting that it was poorly folded. After phosphorylation, this chimera was inactive (Fig. 3). Analysis of its phosphoamino acids after phosphorylation by MEK4 revealed that it was inactive in part because there was little or no threonine phosphorylated (Fig. 4). Domains I and II of ERK2 alter the position of the C helix in the chimera, which may account for the inability of MEKs to phosphorylate threonine.


View larger version (79K):
[in this window]
[in a new window]
  		Fig. 4.   Phosphoamino acid analysis. Phosphoamino acid analysis of p38 and p38II after incubation with MEK3 and EIIP after incubation with MEK4. The positions of the three phosphoamino acid standards are indicated.

The two control proteins were also tested in the in vitro kinase assays to determine whether any residues changed by the insertion of the restriction sites caused the changes in interaction with MEKs. The ERK2 control, ERK2IIright-arrowCT was phosphorylated and activated only by MEK1 and MEK2 (data not shown). Therefore, residues that were changed by the insertion of restriction sites did not affect the productive interaction of ERK2 chimeras with MEKs. The p38 control, p38II, was phosphorylated by MEK3, MEK4, and MEK6 (data not shown). p38II was activated normally by MEK4/6 but less well by MEK3 (data not shown). The phosphoamino acid analysis (Fig. 4) indicates that p38II is not fully activated by MEK3 because it is poorly phosphorylated on threonine.

The maximum stoichiometries of phosphorylation of the chimeras by MEKs 1-4 and 6 were evaluated (Table I) and were consistent with the extents of activation of the chimeras. With the exception of EIIP, the time courses of phosphorylation of the chimeras by individual MEK family members were similar to their rates with their normal substrates, ERK2 or p38 (Figs. 5-7).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Maximum stoichiometry of phosphorylation by MEKs
Maximum stoichiometry of phosphorylation of ERK2, p38, and each chimera is listed as mol PO4/mol MAP kinase. Reactions were performed at 30 °C for 1 h. There was no significant increase in the stoichiometry of phosphorylation at longer times. Data are representative of four or five experiments for each MAP kinase.


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 5.   Time course of phosphorylation and activation of chimeras by MEK2. A, phosphate incorporation into ERK2 (), PIIE (black-triangle), PIVE (black-square), PIVECTP (black-diamond ), and EIIPIVE (black-down-triangle ) by MEK2 at 30 s and 1, 3, 5, 10, 20, 30, 60, and 90 min. B, specific myelin basic protein kinase activity of ERK2 (), PIIE (black-triangle), PIVE (black-square), PIVECTP (black-diamond ), and EIIPIVE (black-down-triangle ) after incubation with MEK2 for the times listed in A. C, immunoblots of ERK2 and chimeras after incubation with MEK2 for the times listed in A. Top, blots were probed with an antibody that specifically recognizes ERK2 or chimeras phosphorylated on both threonine and tyrosine. Bottom, blots were stripped and reprobed with an ERK antibody, Y691, which recognizes both unphosphorylated and phosphorylated ERK2 or chimeras. The exposure time for the PIIE pTEpY blot is longer to allow the bands to be seen.


View larger version (23K):
[in this window]
[in a new window]
  		Fig. 6.   Time course of phosphorylation and activation of chimeras by MEK6. A, phosphate incorporation into p38 (), PIVE (black-triangle), and PIVECTP (black-square) by MEK6 at 5, 10, 20, 30, 60, 90, 120, 180, and 240 min. B, specific myelin basic protein kinase activity of p38 (), PIVE (black-triangle), and PIVECTP (black-square) after incubation with MEK6 for the times listed in A. C, immunoblots of chimeras after incubation with MEK6 for the times listed in A. Top, blots were probed with an antibody that specifically recognizes chimeras phosphorylated on both threonine and tyrosine. Bottom, blots were stripped and reprobed with an ERK antibody, Y691, which recognizes both unphosphorylated and phosphorylated chimeras.


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 7.   Time course of phosphorylation and activation of chimeras by MEK1, MEK3, and MEK4. A, phosphate incorporation into ERK2 (), PIIE (black-triangle), PIVE (black-square), PIVECTP (black-diamond ), and EIIPIVE (black-down-triangle ) after incubation with MEK1 for 5, 10, 15, 20, 30, 60, 90, 120, 180, and 240 min. B, phosphate incorporation into p38 () and PIVECTP (black-triangle) after incubation with MEK3 for the times listed in A. C, phosphate incorporation into p38 () and EIIP (black-triangle) after incubation with MEK4 for the times listed in A.

To determine whether phosphorylation occurred on the predicted residues (Thr183 and Tyr185), chimeras phosphorylated by MEKs for different times were immunoblotted with antibodies that selectively recognize the doubly phosphorylated ERK2 epitope. These antibodies do not detect unphosphorylated or singly phosphorylated ERK2 at equivalent protein concentrations. The immunoblots reveal an excellent parallel between increasing phosphorylation and appearance of the phospho epitope (Figs. 5 and 6). Phosphorylation of the chimeras saturated at the same times as did blotting intensity. This is consistent with the conclusion that phosphorylation occurred largely on Thr183 and Tyr185 and not on previously unidentified residues.

These immunoblotting findings agree with phosphoamino acid analysis, which showed the majority of phosphate on tyrosine and threonine. However, PIVECTP, for example, apparently contained less phosphotyrosine in these analyses than did wild type ERK2. To determine whether this was due to prior autophosphorylation of the chimera, we compared the stoichiometry of phosphorylation of wild type ERK2 and three of the chimeras before and after dephosphorylation with the tyrosine phosphatase PTP1 (Fig. 8A). The stoichiometry of phosphorylation of ERK2 was unchanged by pretreatment with phosphatase; on the other hand, phosphorylation of two of the chimeras increased by 20-30%. The increase was primarily due to increased tyrosine phosphorylation as was apparent from the increase in phosphotyrosine recovered in the phosphoamino acid analysis (Fig. 8, B and C). This is consistent with the idea that the chimeras have enhanced abilities to autophosphorylate on Tyr185 prior to isolation from bacteria. Because this tyrosine is already partly phosphorylated when the proteins are purified, less phosphate can be transferred to tyrosine by MEKs.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 8.   Autophosphorylation accounts for decreased tyrosine phosphorylation of PIVE, PIVECTP, and EIIPIVE by MEK2. A, relative stoichiometry of phosphate incorporation by MEK2 into ERK2, PIVE, PIVECTP, and EIIPIVE without or with pretreatment with PTP1. Data are expressed as the means ± S.E. for three independent experiments. B, phosphoamino acid analysis of ERK2, PIVE, PIVECTP, and EIIPIVE not dephosphorylated with PTP1. C, phosphoamino acid analysis of ERK2, PIVE, PIVECTP, and ERK2IIPIVE first dephosphorylated with PTP1. For B and C, the positions of the three phosphoamino acid standards are indicated.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MEK isoforms recognize members of the MAP kinase family with selectivity. The residues or structural motifs that are required for this selective recognition have not been defined. ERK1/2 and p38 isoforms share about 40-45% sequence identity (5, 36, 37), and the structures of the unphosphorylated forms of ERK2 and p38 are similar (18, 22). The goal of this project was to use chimeras containing swapped structural elements of ERK2 and p38 to identify regions of the MAP kinases that direct interactions with particular MEKs.

Our findings using ERK2/p38 chimeras indicate that no single MAP kinase structural motif forms a sufficient interaction surface with MEK. The N-terminal structural domain likely forms part of the interface. However, even the entire domain is not sufficient to restrict phosphorylation by MEKs, because the chimera containing the N-terminal domain from p38 was phosphorylated by MEK1 and MEK2 in addition to MEK3/4/6. This demonstrates that there are interaction determinants in the C-terminal domain. In addition, a fairly large surface area within the N-terminal domain must be present for the interaction of the chimeras with MEK3/4/6. Swapping only subdomains I and II or subdomains III and IV was not enough to allow MEK3/4/6 to phosphorylate the chimeras. Based on these data, it appears that MEKs require multiple interacting sites within both domains to specifically phosphorylate different MAP kinases.

Our results with ERK2/p38 chimeras are in part consistent with work from Brunet and Pouysségur (31), who expressed p38/ERK1 chimeras in mammalian cells. A p38/ERK1 chimera equivalent to PIVE was activated by both growth factors and cell stress, whereas a chimera equivalent to PIIE was only activated by growth factors. We have shown with further subdivision of the swapped regions that in contrast to the suggestion from the p38/ERK1 studies, the C helix alone is not the key element determining which MEKs will phosphorylate a particular MAP kinase in vitro.

Additional findings suggest that the MAP kinase insert is required for phosphorylation by MEKs. To address the function of this insert, it was deleted from wild type ERK2.2 Examination of the crystal structure indicated that deletion of these residues would have a minimal effect on the tertiary structure of ERK2. In the unphosphorylated state, the resulting protein had protein kinase activity equivalent to unphosphorylated wild type ERK2. However, the protein lacking the MAP kinase insert was no longer phosphorylated by MEK2 in vitro.2 It is possible that the insert aids in the correct folding of the phosphorylation lip, for binding to MEKs, or that it may be directly involved in interaction with MEKs.

We mapped the currently available data for MEK specificity determinants onto the structure of unphosphorylated ERK2 (Fig. 9). The data reported here indicate that the C helix, beta  strands 4 and 5, and L16 of MAP kinase are important, because when these motifs are from ERK2, phosphorylation by MEK3/4/6 is lost. The findings noted above suggest a role for the MAP kinase insert. In addition, previous work showed that mutating tyrosine 185 in the phosphorylation lip or deleting six residues from this loop of ERK2 resulted in significantly decreased phosphorylation by MEK1 and MEK2 (29, 32). Taken together, the regions of a MAP kinase that appear to be important for the MEK/MAP kinase interaction include the vicinity of the C helix and L16 from the N-terminal domain and include the phosphorylation lip region and the MAP kinase insert from the C-terminal domain. These experimental findings are in good agreement with a visually generated model of the ERK2/MEK1 interface. The model was created by mapping MEK1 residues onto the coordinates of the cAMP-dependent protein kinase (14) and manually docking with the ERK2 coordinates. The ERK2 phosphorylation lip was placed on MEK1 in the position of the bound peptide substrate (16). The sites of contact in this hypothetical ERK2/MEK1 model include residues from each of the structural elements implicated experimentally, namely, the tip of the C helix, the loop region of L16, the phosphorylation lip, and the tip of the MAP kinase insert.


View larger version (49K):
[in this window]
[in a new window]
  		Fig. 9.   Structural representation of ERK2 motifs that are important for the MEK/MAP kinase interaction. ERK2 residues that appear to be required for the interaction with MEK are yellow. Residues not implicated in MEK binding in the N-terminal domain are in green, and residues not implicated in MEK binding in the C-terminal domain are in blue. The figure was generated in InsightII (Molecular Biosystems).

The proposed MEK/MAP kinase interface is involved in other protein-protein interactions. Residues in this putative interface overlap with the ERK2 dimerization interface (38). In particular, L16 and the phosphorylation lip are intimately involved in both. Furthermore, it is intriguing that the proposed MEK/MAP kinase interface is similar to the interface between Cdk2 and cyclin A (21). Structural elements of Cdk2 that participate in cyclin A binding include the PSTAIRE helix region, which encompasses the helix equivalent to the C helix of MAP kinases and the beta 4 and beta 5 strands. In the C-terminal domain, contacts with cyclin A are made by residues in the region of the T loop, equivalent to the ERK2 phosphorylation lip, and a C-terminal helix, helix 7. The only motif that participates in the proposed MEK/ERK interface but not in the Cdk2/cyclin A interface is the MAP kinase insert.

    ACKNOWLEDGEMENTS

We thank Megan Robinson and Meg Phillips for helpful suggestions and comments about the manuscript and Tina Arikan for assistance in its preparation.

    FOOTNOTES

* This work was supported by Grant I1243 from the Welch Foundation and Grant DK34128 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by a predoctoral fellowship from the Howard Hughes Medical Institute. This work was completed in partial fulfillment of the requirements for the Ph.D. degree.

parallel To whom correspondence should be addressed: Dept. of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9041. Tel.: 214-648-3627; Fax: 214-648-3811.

2 J. L. Wilsbacher and M. H. Cobb, unpublished results.

    ABBREVIATIONS

The abbreviations used are: MAP, mitogen-activated protein; ERK, extracellular signal-regulated protein kinase; MEK, MAP/ERK kinase; MEKK, MEK kinase; PTP1, protein-tyrosine phosphatase, type 1.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Cancer Res. 74, 49-139
  2. Robinson, M. J., and Cobb, M. H. (1997) Curr. Opin. Cell Biol. 9, 180-186[CrossRef][Medline] [Order article via Infotrieve]
  3. Neiman, A. M., Stevenson, B. J., Xu, H.-P., Sprague, G. F., Jr., Herskowitz, I., Wigler, M., and Marcus, S. (1993) Mol. Biol. Cell 4, 107-120[Abstract]
  4. Boulton, T. G., and Cobb, M. H. (1991) Cell Regul. 2, 357-371[Medline] [Order article via Infotrieve]
  5. Boulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radziejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., and Yancopoulos, G. D. (1991) Cell 65, 663-675[CrossRef][Medline] [Order article via Infotrieve]
  6. Gonzalez, F. A., Raden, D. L., Rigby, M. R., and Davis, R. J. (1992) FEBS Lett. 304, 170-178[CrossRef][Medline] [Order article via Infotrieve]
  7. Zhou, G., Bao, Z. Q., and Dixon, J. E. (1995) J. Biol. Chem. 270, 12665-12669[Abstract/Free Full Text]
  8. Lee, J.-D., Ulevitch, R. J., and Han, J. (1995) Biochem. Biophys. Res. Commun. 213, 715-724[CrossRef][Medline] [Order article via Infotrieve]
  9. Jiang, Y., Gram, H., Zhao, M., New, L., Gu, J., Feng, L., Di Padova, F., Ulevitch, R. J., and Han, J. (1997) J. Biol. Chem. 272, 30122-30128[Abstract/Free Full Text]
  10. Li, Z., Jiang, Y., Ulevitch, R. J., and Han, J. (1996) Biochem. Biophys. Res. Commun. 228, 334-340[CrossRef][Medline] [Order article via Infotrieve]
  11. Lechner, C., Zahalka, M. A., Giot, J. F., Moller, N. P., and Ullrich, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4355-4359[Abstract/Free Full Text]
  12. Goldsmith, E., and Cobb, M. H. (1994) Curr. Opin. Struct. Biol. 4, 833-840[CrossRef][Medline] [Order article via Infotrieve]
  13. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52[Abstract/Free Full Text]
  14. Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., and Sowadski, J. M. (1991) Science 253, 407-413[Abstract/Free Full Text]
  15. Hanks, S. K., and Hunter, T. (1995) FASEB J. 9, 576-596[Abstract]
  16. Knighton, D. R., Zheng, J., Ten Eyck, L. F., Xuong, N.-H., Taylor, S. S., and Sowadski, J. M. (1991) Science 253, 414-429[Abstract/Free Full Text]
  17. Taylor, S. S., Knighton, D. R., Zheng, J., Sowadski, J. M., Gibbs, C. S., and Zoller, M. J. (1993) Trends Biochem. Sci. 18, 84-89[CrossRef][Medline] [Order article via Infotrieve]
  18. Zhang, F., Strand, A., Robbins, D., Cobb, M. H., and Goldsmith, E. J. (1994) Nature 367, 704-710[CrossRef][Medline] [Order article via Infotrieve]
  19. Xu, W., Harrison, S. C., and Eck, M. J. (1997) Nature 385, 595-602[CrossRef][Medline] [Order article via Infotrieve]
  20. DeBondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O., and Kim, S.-H. (1993) Nature 363, 595-602[CrossRef][Medline] [Order article via Infotrieve]
  21. Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and Pavletich, N. P. (1995) Nature 376, 313-320[CrossRef][Medline] [Order article via Infotrieve]
  22. Wang, Z., Harkins, P. C., Ulevitch, R. J., Han, J., Cobb, M. H., and Goldsmith, E. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2327-2332[Abstract/Free Full Text]
  23. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., and Goldsmith, E. (1997) Cell 90, 859-869[CrossRef][Medline] [Order article via Infotrieve]
  24. Wilson, K. P., Fitzgibbon, M. J., Caron, P. R., Griffith, J. P., Chen, W., McCaffrey, P. G., Chambers, S. P., and Su, M. S. S. (1996) J. Biol. Chem. 271, 27696-27700[Abstract/Free Full Text]
  25. Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., Cobb, M. H., and Krebs, E. G. (1992) J. Biol. Chem. 267, 14373-14381[Abstract/Free Full Text]
  26. Dérijard, B., Raingeaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682-685[Abstract/Free Full Text]
  27. Stein, B., Brady, H., Yang, M. X., Young, D. B., and Barbosa, M. S. (1996) J. Biol. Chem. 271, 11427-11433[Abstract/Free Full Text]
  28. Kato, Y., Kravchecnko, V. V., Tapping, R. I., Han, J., Ulevitch, R. J., and Lee, J. D. (1997) EMBO J. 16, 7054-7066[CrossRef][Medline] [Order article via Infotrieve]
  29. Robinson, M. J., Cheng, M., Khokhlatchev, A., Ebert, D., Ahn, N., Guan, K.-L., Stein, B., Goldsmith, E., and Cobb, M. H. (1996) J. Biol. Chem. 271, 29734-29739[Abstract/Free Full Text]
  30. Jiang, Y., Li, Z., Schwarz, E. M., Lin, A., Guan, K., Ulevitch, R. J., and Han, J. (1998) J. Biol. Chem. 272, 11096-11102[Abstract/Free Full Text]
  31. Brunet, A., and Pouysségur, J. (1996) Science 272, 1653-1655
  32. Robbins, D. J., Zhen, E., Owaki, H., Vanderbilt, C., Ebert, D., Geppert, T. D., and Cobb, M. H. (1993) J. Biol. Chem. 268, 5097-5106[Abstract/Free Full Text]
  33. Khokhlatchev, A., Xu, S., English, J., Wu, P., Schaefer, E., and Cobb, M. H. (1997) J. Biol. Chem. 272, 11057-11062[Abstract/Free Full Text]
  34. Xu, S., Robbins, D., Frost, J., Dang, A., Lange-Carter, C., and Cobb, M. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 6808-6812[Abstract/Free Full Text]
  35. Robbins, D. J., and Cobb, M. H. (1992) Mol. Biol. Cell 3, 299-308[Abstract]
  36. Han, J., Lee, J.-D., Bibbs, L., and Ulevitch, R. J. (1994) Science 265, 808-811[Abstract/Free Full Text]
  37. Zheng, C. F., Ohmichi, M., Saltiel, A. R., and Guan, K.-L. (1994) Biochemistry 33, 5595-5599[CrossRef][Medline] [Order article via Infotrieve]
  38. Khokhlatchev, A., Canagarajah, B. J., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E. J., and Cobb, M. H. (1998) Cell 93, 605-615[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JDRHome page
C.S. Patil and K.L. Kirkwood
p38 MAPK Signaling in Oral-related Diseases
Journal of Dental Research, September 1, 2007; 86(9): 812 - 825.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Polychronopoulos, M. Verykokakis, M. N. Yazicioglu, M. Sakarellos-Daitsiotis, M. H. Cobb, and G. Mavrothalassitis
The Transcriptional ETS2 Repressor Factor Associates with Active and Inactive Erks through Distinct FXF Motifs
J. Biol. Chem., September 1, 2006; 281(35): 25601 - 25611.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Tarrega, P. Rios, R. Cejudo-Marin, C. Blanco-Aparicio, L. van den Berk, J. Schepens, W. Hendriks, L. Tabernero, and R. Pulido
ERK2 Shows a Restrictive and Locally Selective Mechanism of Recognition by Its Tyrosine Phosphatase Inactivators Not Shared by Its Activator MEK1
J. Biol. Chem., November 11, 2005; 280(45): 37885 - 37894.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. W. Whitehurst, F. L. Robinson, M. S. Moore, and M. H. Cobb
The Death Effector Domain Protein PEA-15 Prevents Nuclear Entry of ERK2 by Inhibiting Required Interactions
J. Biol. Chem., March 26, 2004; 279(13): 12840 - 12847.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F.-L. Chou, J. M. Hill, J.-C. Hsieh, J. Pouyssegur, A. Brunet, A. Glading, F. Uberall, J. W. Ramos, M. H. Werner, and M. H. Ginsberg
PEA-15 Binding to ERK1/2 MAPKs Is Required for Its Modulation of Integrin Activation
J. Biol. Chem., December 26, 2003; 278(52): 52587 - 52597.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. W.-C. Li, J.-P. Liu, J. Wang, Y.-W. Mao, and L.-H. Hou
Expression and Activity of the Signaling Molecules for Mitogen-Activated Protein Kinase Pathways in Human, Bovine, and Rat Lenses
Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5277 - 5286.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. T. Ho, A. J. Bardwell, M. Abdollahi, and L. Bardwell
A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates
J. Biol. Chem., August 29, 2003; 278(35): 32662 - 32672.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Shibayama, R. Shibata-Seita, K. Miura, Y. Kirino, and K. Takishima
Identification of a C-terminal Region That Is Required for the Nuclear Translocation of ERK2 by Passive Diffusion
J. Biol. Chem., September 27, 2002; 277(40): 37777 - 37782.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. T. Eblen, J. K. Slack, M. J. Weber, and A. D. Catling
Rac-PAK Signaling Stimulates Extracellular Signal-Regulated Kinase (ERK) Activation by Regulating Formation of MEK1-ERK Complexes
Mol. Cell. Biol., September 1, 2002; 22(17): 6023 - 6033.
[Abstract] [Full Text] [PDF]